预测免疫检查点抑制剂治疗肝细胞癌疗效方法的研究进展  

Research progress of the methods for predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma treatment

作　　者：秦然 徐锋[1] Qin Ran;Xu Feng(Department of General Surgery,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院普通外科,沈阳110004

出　　处：《中华肝胆外科杂志》2023年第8期632-636,共5页Chinese Journal of Hepatobiliary Surgery

基　　金：辽宁省自然科学基金(20180551193、2020-MS-181);盛京医院345人才工程计划(40B)。

摘　　要：近年来,免疫检查点抑制剂(ICIs)在中晚期肝细胞癌治疗中发挥了重要作用,使得部分患者从中获益。现阶段ICIs治疗肝细胞癌仍然存在客观缓解率有限、治疗费用较高、治疗相关不良事件频发、肿瘤超进展等诸多问题。在此背景下,寻找能够预测ICIs治疗效果的指标,可优化患者选择、以最大限度发挥其临床效益,避免不必要的不良反应和经济损失。本文从生化与细胞学指标、肿瘤相关标志物、影像学指标、免疫相关不良事件等方面进行阐述,以期能为临床治疗提供参考。In recent years,immune checkpoint inhibitors(ICIs)have emerged as a significant advancement in the treatment of advanced hepatocellular carcinoma(HCC),providing benefits to a subset of patients.At present,there are still many problems with ICIs treatment for HCC,such as limited objective remission rate,high treatment cost,frequent treatment-related adverse events,and tumor hyperprogression.In this context,it is important to find indicators that can predict the efficacy of ICIs treatment in order to optimize patients’selection and maximize clinical benefits,further avoiding unnecessary toxic side effects and economic losses.This article discusses biochemical and cytological indicators,tumor-related markers,imaging indicators,and immune-related adverse events in order to guide clinical treatment.

关 键 词：癌 肝细胞 免疫检查点抑制剂 治疗 

分 类 号：R735.7[医药卫生—肿瘤]